nalidixic acid has been researched along with Typhoid Fever in 46 studies
Typhoid Fever: An acute systemic febrile infection caused by SALMONELLA TYPHI, a serotype of SALMONELLA ENTERICA.
| Excerpt | Relevance | Reference |
|---|---|---|
| ", resistant to chloramphenicol, ampicillin, and cotrimoxazole) and nalidixic acid-resistant enteric fever, azithromycin (1 g once daily for 5 days at 20 mg/kg/day) and ofloxacin (200 mg orally twice a day for 5 days at 8 mg/kg/day) were compared in an open randomized study in adults admitted to a hospital with uncomplicated enteric fever." | 9.09 | A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. ( Chinh, NT; Diep, TS; Farrar, JJ; Ha, HD; Ly, NT; Parry, CM; Thong, MX; Wain, J; White, NJ, 2000) |
| "The purpose of this study was to examine the rate and clinical consequences of nalidixic acid-resistant (NAR) isolates in travellers with enteric fever presenting to a hospital in a developed country." | 7.75 | Increasing rates and clinical consequences of nalidixic acid-resistant isolates causing enteric fever in returned travellers: an 18-year experience. ( Hume, S; Korman, T; Schulz, T; Torresi, J; Vinton, P, 2009) |
| "Enteric fever is a global health problem and there is emerging drug resistance with some reports of re-emerging sensitivity to previously used antibiotics eg, chloramphenicol." | 7.75 | Changing antibiotic sensitivity pattern and scope of chloramphenicol in the management of hospitalised patients of typhoid fever. ( Abqari, S; Ahmad, F; Beig, FK, 2009) |
| "Uncomplicated typhoid fever due to isolates of MDR S." | 6.73 | Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. ( Bay, PV; Farrar, JJ; Hien, TT; Ho, VA; Lanh, MN; Parry, CM; Phuong, le T; Tham, NT; Tung, le T; Wain, J, 2007) |
| "The epidemiology of typhoid fever in South Asia has changed." | 5.48 | Effectiveness of treatment regimens for Typhoid fever in the nalidixic acid-resistant S. typhi (NARST) era in South India. ( Balaji, V; Bandyopadhyay, R; Jasmine, S; Rupali, P; Sathyendra, S; Yadav, B, 2018) |
| ", resistant to chloramphenicol, ampicillin, and cotrimoxazole) and nalidixic acid-resistant enteric fever, azithromycin (1 g once daily for 5 days at 20 mg/kg/day) and ofloxacin (200 mg orally twice a day for 5 days at 8 mg/kg/day) were compared in an open randomized study in adults admitted to a hospital with uncomplicated enteric fever." | 5.09 | A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. ( Chinh, NT; Diep, TS; Farrar, JJ; Ha, HD; Ly, NT; Parry, CM; Thong, MX; Wain, J; White, NJ, 2000) |
| "Nalidixic acid resistance has become widespread in enteric fever isolates from the Indian subcontinent and some parts of South-East Asia, justifying the use of ceftriaxone or azithromycin rather than ciprofloxacin as first-line treatment." | 3.78 | Twenty-six years of enteric fever in Australia: an epidemiological analysis of antibiotic resistance. ( Commons, RJ; Hogg, G; McBryde, E; Powling, J; Street, A; Valcanis, M, 2012) |
| "The purpose of this study was to examine the rate and clinical consequences of nalidixic acid-resistant (NAR) isolates in travellers with enteric fever presenting to a hospital in a developed country." | 3.75 | Increasing rates and clinical consequences of nalidixic acid-resistant isolates causing enteric fever in returned travellers: an 18-year experience. ( Hume, S; Korman, T; Schulz, T; Torresi, J; Vinton, P, 2009) |
| "Enteric fever is a global health problem and there is emerging drug resistance with some reports of re-emerging sensitivity to previously used antibiotics eg, chloramphenicol." | 3.75 | Changing antibiotic sensitivity pattern and scope of chloramphenicol in the management of hospitalised patients of typhoid fever. ( Abqari, S; Ahmad, F; Beig, FK, 2009) |
| "The last two decades have seen a change in the pattern of enteric fever with the emergence of multidrug-resistant strains (MDRS), particularly strains resistant to nalidixic acid." | 3.73 | Current perspectives of enteric fever: a hospital-based study from India. ( Aggarwal, P; Gaind, R; Kalaivani, M; Mehta, R; Paul, P; Walia, M, 2005) |
| "Uncomplicated typhoid fever due to isolates of MDR S." | 2.73 | Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. ( Bay, PV; Farrar, JJ; Hien, TT; Ho, VA; Lanh, MN; Parry, CM; Phuong, le T; Tham, NT; Tung, le T; Wain, J, 2007) |
| "Typhoid fever is endemic in most countries, causing major public health problems with high morbidity and mortality, the resistance of Salmonella enterica serovar Typhi (S." | 1.56 | Molecular Detection of ( Habeeb Rasool, K; Hammood Hussein, N; Mahamed Taha, B, 2020) |
| "The epidemiology of typhoid fever in South Asia has changed." | 1.48 | Effectiveness of treatment regimens for Typhoid fever in the nalidixic acid-resistant S. typhi (NARST) era in South India. ( Balaji, V; Bandyopadhyay, R; Jasmine, S; Rupali, P; Sathyendra, S; Yadav, B, 2018) |
| "Typhoid fever is a major cause of morbidity and mortality in the developing countries including India." | 1.46 | Characterization of antimicrobial resistance markers & their stability in ( Kumar, Y; Mani, KR; Sharma, A, 2017) |
| "Typhoid fever is a food- and water-borne disease, caused by Salmonella enterica serovar Typhi, responsible for high rates of morbidity and mortality in developing countries." | 1.37 | [Antibiotic susceptibility of Salmonella enterica serovar Typhi isolated from blood cultures at the Ain M'lila hospital (Algeria), between 2005 and 2008]. ( Boudersa, F; Bouzenoune, F; Kellab Debbih, K; Kouhil, S; Nezzar, N, 2011) |
| "Typhoid and paratyphoid fever are endemic in China." | 1.36 | Genetic diversity of Salmonella enteric serovar typhi and paratyphi in Shenzhen, China from 2002 through 2007. ( Chen, M; Lu, J; Lu, Y; Wang, H; Wu, J; Wu, W; Xu, Y, 2010) |
| "Typhoid fever is a systemic intracellular infection caused by Salmonellaenterica serotype Typhi." | 1.36 | In vitro efficacy of the combination of ciprofloxacin and cefotaxime against nalidixic acid-resistant Salmonella enterica serotype Typhi. ( Jang, SJ; Kim, DM; Kim, SH; Lee, BK; Neupane, GP, 2010) |
| "The patient was treated for presumptive typhoid fever with ciprofloxacin." | 1.35 | Early small bowel perforation and cochleovestibular impairment as rare complications of typhoid fever. ( Lahri, H; Petit, PL; van Genderen, PJ; van Wolfswinkel, ME; Wismans, PJ, 2009) |
| "Nalidixic acid resistance has been used as an indirect evidence of increased minimum inhibitory concentration for ciprofloxacin in Salmonella Typhi." | 1.35 | High level of resistance to nalidixic acid in Salmonella enterica serovar Typhi in Central India. ( Kumar, Y; Mani, KR; Sharma, A, 2009) |
| "Low-level quinolone-resistance in typhoid was high in this small series." | 1.35 | Low-level quinolone-resistance in multi-drug resistant typhoid. ( Khan, MA; Mirza, SH, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (8.70) | 18.7374 |
| 1990's | 1 (2.17) | 18.2507 |
| 2000's | 25 (54.35) | 29.6817 |
| 2010's | 12 (26.09) | 24.3611 |
| 2020's | 4 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Nathania, I | 1 |
| Nainggolan, IM | 1 |
| Yasmon, A | 1 |
| Nusatia, ACM | 1 |
| Tjoa, E | 1 |
| Gunardi, WD | 1 |
| Moehario, LH | 1 |
| Shrestha, SK | 1 |
| Khadka, S | 1 |
| Rayamajhee, B | 1 |
| Thapa, A | 1 |
| Sharma, S | 1 |
| Shrestha, B | 1 |
| Poudel, P | 1 |
| Habeeb Rasool, K | 1 |
| Hammood Hussein, N | 1 |
| Mahamed Taha, B | 1 |
| Prabhurajan, R | 1 |
| Selvam, RME | 1 |
| Padmavathy, K | 1 |
| Kumar, Y | 2 |
| Sharma, A | 2 |
| Mani, KR | 2 |
| Bandyopadhyay, R | 1 |
| Balaji, V | 1 |
| Yadav, B | 1 |
| Jasmine, S | 1 |
| Sathyendra, S | 1 |
| Rupali, P | 1 |
| Choudhary, A | 1 |
| Gopalakrishnan, R | 1 |
| Nambi, PS | 1 |
| Ramasubramanian, V | 1 |
| Ghafur, KA | 1 |
| Thirunarayan, MA | 1 |
| Chiou, CS | 1 |
| Lauderdale, TL | 1 |
| Phung, DC | 1 |
| Watanabe, H | 1 |
| Kuo, JC | 1 |
| Wang, PJ | 1 |
| Liu, YY | 1 |
| Liang, SY | 1 |
| Chen, PC | 1 |
| Kadhiravan, T | 2 |
| Wig, N | 2 |
| Renuka, K | 2 |
| Kapil, A | 2 |
| Kabra, SK | 2 |
| Misra, A | 2 |
| Hume, S | 1 |
| Schulz, T | 1 |
| Vinton, P | 1 |
| Korman, T | 1 |
| Torresi, J | 1 |
| Smith, AM | 1 |
| Govender, N | 1 |
| Keddy, KH | 1 |
| van Wolfswinkel, ME | 1 |
| Lahri, H | 1 |
| Wismans, PJ | 1 |
| Petit, PL | 2 |
| van Genderen, PJ | 2 |
| Wu, W | 1 |
| Wang, H | 1 |
| Lu, J | 1 |
| Wu, J | 1 |
| Chen, M | 1 |
| Xu, Y | 1 |
| Lu, Y | 1 |
| Kim, DM | 1 |
| Neupane, GP | 1 |
| Jang, SJ | 1 |
| Kim, SH | 1 |
| Lee, BK | 1 |
| Beig, FK | 1 |
| Ahmad, F | 1 |
| Abqari, S | 1 |
| Gaborieau, V | 1 |
| Weill, FX | 1 |
| Marchou, B | 1 |
| Bouzenoune, F | 1 |
| Kellab Debbih, K | 1 |
| Boudersa, F | 1 |
| Kouhil, S | 1 |
| Nezzar, N | 1 |
| Hassing, RJ | 1 |
| Menezes, GA | 1 |
| van Pelt, W | 1 |
| Goessens, WH | 1 |
| Commons, RJ | 1 |
| McBryde, E | 1 |
| Valcanis, M | 1 |
| Powling, J | 1 |
| Street, A | 1 |
| Hogg, G | 1 |
| Acharya, D | 1 |
| Trakulsomboon, S | 1 |
| Madhup, SK | 1 |
| Korbsrisate, S | 1 |
| Asna, SM | 1 |
| Haq, JA | 2 |
| Rahman, MM | 2 |
| Crump, JA | 1 |
| Barrett, TJ | 1 |
| Nelson, JT | 1 |
| Angulo, FJ | 1 |
| Parry, CM | 3 |
| Slinger, R | 1 |
| Desjardins, M | 1 |
| McCarthy, AE | 1 |
| Ramotar, K | 1 |
| Jessamine, P | 1 |
| Guibord, C | 1 |
| Toye, B | 1 |
| Panhotra, BR | 1 |
| Saxena, AK | 1 |
| Al-Ghamdi, AM | 1 |
| Shakespeare, WA | 1 |
| Davie, D | 1 |
| Tonnerre, C | 1 |
| Rubin, MA | 1 |
| Strong, M | 1 |
| Petti, CA | 1 |
| Lewis, MD | 1 |
| Serichantalergs, O | 1 |
| Pitarangsi, C | 1 |
| Chuanak, N | 1 |
| Mason, CJ | 1 |
| Regmi, LR | 1 |
| Pandey, P | 1 |
| Laskar, R | 1 |
| Shrestha, CD | 1 |
| Malla, S | 1 |
| Morshed, MA | 1 |
| Rahman, MA | 1 |
| Nkemngu, NJ | 1 |
| Asonganyi, ED | 1 |
| Njunda, AL | 1 |
| Walia, M | 1 |
| Gaind, R | 1 |
| Mehta, R | 1 |
| Paul, P | 1 |
| Aggarwal, P | 1 |
| Kalaivani, M | 1 |
| Cooke, FJ | 1 |
| Wain, J | 3 |
| Threlfall, EJ | 1 |
| Ho, VA | 1 |
| Phuong, le T | 1 |
| Bay, PV | 1 |
| Lanh, MN | 1 |
| Tung, le T | 1 |
| Tham, NT | 1 |
| Hien, TT | 1 |
| Farrar, JJ | 2 |
| Kownhar, H | 1 |
| Shankar, EM | 1 |
| Rajan, R | 1 |
| Rao, UA | 1 |
| Khanal, B | 1 |
| Sharma, SK | 1 |
| Bhattacharya, SK | 1 |
| Bhattarai, NR | 1 |
| Deb, M | 1 |
| Kanungo, R | 1 |
| González-López, JJ | 1 |
| Larrosa, N | 1 |
| Planes, AM | 1 |
| Bartolomé-Comas, RM | 1 |
| Al-Khuwaitir, TS | 1 |
| Al-Zuhair, AA | 1 |
| Al-Ghamdi, AG | 1 |
| Khan, A | 1 |
| Mirza, SH | 1 |
| Khan, MA | 1 |
| Chinh, NT | 1 |
| Ly, NT | 1 |
| Ha, HD | 1 |
| Thong, MX | 1 |
| Diep, TS | 1 |
| White, NJ | 1 |
| Rodrigues, C | 1 |
| Mehta, A | 1 |
| Joshi, VR | 1 |
| Ciraj, AM | 1 |
| Seema, DS | 1 |
| Bhat, GK | 1 |
| Shivananda, PG | 1 |
| Dawkins, AT | 1 |
| Hornick, RB | 1 |
| Smith, HW | 1 |
| Hassan, A | 1 |
| Wahab, MF | 1 |
| Farid, Z | 1 |
| el-Rooby, AS | 1 |
| Hiraishi, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Azithromycin and Cefixime Combination Versus Azithromycin Alone for the Out-patient Treatment of Clinically Suspected or Confirmed Uncomplicated Typhoid Fever in South Asia; a Randomised Controlled Trial[NCT04349826] | Phase 4 | 1,500 participants (Anticipated) | Interventional | 2021-05-23 | Recruiting | ||
| Parallel Group, Double Blinded, 1:1, Randomized Controlled Phase III Trial of Co-trimoxazole Versus Azithromycin for the Treatment of Undifferentiated Fever In Nepal[NCT02773407] | Phase 3 | 330 participants (Actual) | Interventional | 2016-05-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for nalidixic acid and Typhoid Fever
| Article | Year |
|---|---|
The treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever in Viet Nam.
Topics: Adolescent; Adult; Age Distribution; Aged; Anti-Infective Agents; Azithromycin; Cephalosporins; Chil | 2004 |
Nalidixic acid-resistant Salmonella enterica serotype Typhi presenting as a primary psoas abscess: case report and review of the literature.
Topics: Adult; Anti-Infective Agents; Drug Resistance, Bacterial; Humans; Male; Microbial Sensitivity Tests; | 2005 |
3 trials available for nalidixic acid and Typhoid Fever
| Article | Year |
|---|---|
Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Blood Cell Count; Child; Child, Preschool; D | 2007 |
Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Blood Cell Count; Child; Child, Preschool; D | 2007 |
Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Blood Cell Count; Child; Child, Preschool; D | 2007 |
Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Blood Cell Count; Child; Child, Preschool; D | 2007 |
A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Drug Resistance, Mult | 2000 |
A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Drug Resistance, Mult | 2000 |
A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Drug Resistance, Mult | 2000 |
A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Drug Resistance, Mult | 2000 |
Evaluation of antibiotics in a typhoid model.
Topics: Anti-Bacterial Agents; Clinical Trials as Topic; Humans; Male; Models, Biological; Nalidixic Acid; T | 1966 |
41 other studies available for nalidixic acid and Typhoid Fever
| Article | Year |
|---|---|
Hotspots sequences of gyrA, gyrB, parC, and parE genes encoded for fluoroquinolones resistance from local Salmonella Typhi strains in Jakarta.
Topics: Amino Acids; Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance | 2022 |
Lower Susceptibility to Fluoroquinolones and a gyrA Gene Mutation in Salmonella Typhi Isolates from Enteric Fever Patients.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity T | 2022 |
Molecular Detection of
Topics: Agar; Anti-Bacterial Agents; Anti-Infective Agents; Cefazolin; Cefepime; Ciprofloxacin; DNA Gyrase; | 2020 |
Unusual antibiotic resistance pattern among blood culture isolates of Salmonella Paratyphi A.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; India; Microb | 2021 |
Characterization of antimicrobial resistance markers & their stability in
Topics: Ampicillin; Anti-Bacterial Agents; Chloramphenicol; Drug Resistance, Multiple, Bacterial; Humans; In | 2017 |
Effectiveness of treatment regimens for Typhoid fever in the nalidixic acid-resistant S. typhi (NARST) era in South India.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Cohort Studies; Dr | 2018 |
Antimicrobial susceptibility of Salmonella enterica serovars in a tertiary care hospital in southern India.
Topics: Ampicillin; Chloramphenicol; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bac | 2013 |
Antimicrobial resistance in Salmonella enterica Serovar Typhi isolates from Bangladesh, Indonesia, Taiwan, and Vietnam.
Topics: Anti-Bacterial Agents; Bangladesh; Base Sequence; Carrier Proteins; Ciprofloxacin; Drug Resistance, | 2014 |
Is nalidixic acid resistance linked to clinical virulence in Salmonella enterica serovar Typhi infections?
Topics: Adolescent; Adult; Anti-Infective Agents; Drug Resistance, Bacterial; Female; Humans; Male; Nalidixi | 2008 |
Increasing rates and clinical consequences of nalidixic acid-resistant isolates causing enteric fever in returned travellers: an 18-year experience.
Topics: Adolescent; Adult; Aged; Animals; Anti-Bacterial Agents; Australia; Drug Resistance, Bacterial; Fema | 2009 |
Quinolone-resistant Salmonella Typhi in South Africa, 2003-2007.
Topics: Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Genotype; Hum | 2010 |
Early small bowel perforation and cochleovestibular impairment as rare complications of typhoid fever.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cochlear Diseases; Drug Resistance, Bacterial; Female; Hum | 2009 |
High level of resistance to nalidixic acid in Salmonella enterica serovar Typhi in Central India.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Drug Resistance, B | 2009 |
Genetic diversity of Salmonella enteric serovar typhi and paratyphi in Shenzhen, China from 2002 through 2007.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; China; DNA, Bacterial; Drug Resistance, Bacterial; | 2010 |
In vitro efficacy of the combination of ciprofloxacin and cefotaxime against nalidixic acid-resistant Salmonella enterica serotype Typhi.
Topics: Anti-Infective Agents; Cefotaxime; Ciprofloxacin; Drug Resistance, Bacterial; Drug Synergism; Humans | 2010 |
Changing antibiotic sensitivity pattern and scope of chloramphenicol in the management of hospitalised patients of typhoid fever.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Chloramphenicol; Drug Resistance, Multip | 2009 |
[A case of Salmonella enterica serovar typhi with decreased susceptibility to ciprofloxacin].
Topics: Anti-Bacterial Agents; Bacteremia; Ceftriaxone; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; | 2010 |
[Antibiotic susceptibility of Salmonella enterica serovar Typhi isolated from blood cultures at the Ain M'lila hospital (Algeria), between 2005 and 2008].
Topics: Algeria; Ampicillin; Anti-Bacterial Agents; Bacteremia; Catchment Area, Health; Chloramphenicol; Dev | 2011 |
Analysis of mechanisms involved in reduced susceptibility to ciprofloxacin in Salmonella enterica serotypes Typhi and Paratyphi A isolates from travellers to Southeast Asia.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Asia, Southeastern; Blood; Ciprofloxacin; DNA Gyrase | 2011 |
Twenty-six years of enteric fever in Australia: an epidemiological analysis of antibiotic resistance.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Asia, Southeastern; Australia; Ch | 2012 |
Antibiotic susceptibility pattern and the indicator of decreased ciprofloxacin susceptibility of Salmonella enterica serovar Typhi isolated from Dhulikhel Hospital, Nepal.
Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA, Bacterial; Drug Resistance, Bacterial; Hospit | 2012 |
Nalidixic acid-resistant Salmonella enterica serovar Typhi with decreased susceptibility to ciprofloxacin caused treatment failure: a report from Bangladesh.
Topics: Adult; Bangladesh; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Humans; Male; Microbial Sens | 2003 |
Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae.
Topics: Anti-Infective Agents; Disease Models, Animal; Drug Resistance, Bacterial; Fluoroquinolones; Humans; | 2003 |
Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series.
Topics: Anti-Infective Agents; Bacteremia; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Humans; Micr | 2004 |
Typhoid fever due to multiresistant Salmonella enterica serovar typhi having reduced susceptibility to ciprofloxacin and nalidixic acid resistance.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Blood Chemical Analysis; Child, Preschool; Ciprofloxacin; | 2004 |
Typhoid fever: a massive, single-point source, multidrug-resistant outbreak in Nepal.
Topics: Adult; Anti-Bacterial Agents; Culture Media; Disease Outbreaks; Drug Resistance, Multiple, Bacterial | 2005 |
Salmonella enterica serovar Typhi with decreased susceptibility to ciprofloxacin--an emerging problem in Bangladesh.
Topics: Anti-Bacterial Agents; Bangladesh; Ciprofloxacin; Drug Resistance, Bacterial; Hospitals, Urban; Huma | 2005 |
Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Child; Child, Preschool; Ciprofloxacin; Drug Res | 2005 |
Treatment failure in a typhoid patient infected with nalidixic acid resistant S. enterica serovar Typhi with reduced susceptibility to ciprofloxacin: a case report from Cameroon.
Topics: Adult; Anti-Bacterial Agents; Cameroon; Ceftriaxone; Ciprofloxacin; Drug Resistance, Multiple, Bacte | 2005 |
Current perspectives of enteric fever: a hospital-based study from India.
Topics: Adolescent; Adult; Age Distribution; Anti-Infective Agents; Child; Child, Preschool; Ciprofloxacin; | 2005 |
Fluoroquinolone resistance in Salmonella Typhi.
Topics: Anti-Infective Agents; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Nalidixic Acid; Salmon | 2006 |
Emergence of nalidixic acid-resistant Salmonella enterica serovar Typhi resistant to ciprofloxacin in India.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; HIV Infections; Humans; | 2007 |
Antimicrobial susceptibility patterns of Salmonella enterica serotype typhi in eastern Nepal.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Colony Count, Microbial; Dose-Response Relationship, Drug; Dru | 2007 |
[About a patient with nalidixic-acid-resistant Salmonella enterica serotype typhi infection. Therapeutic management].
Topics: Adolescent; Bacteremia; Bacterial Proteins; Campylobacter Infections; Campylobacter jejuni; DNA Gyra | 2007 |
Nalidixic acid-resistant Salmonella enterica serotype typhi infection presenting with sub-intestinal obstruction and mesenteric adenitis.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Diagnosis, Differential; Drug Resistance, Bacterial; Fe | 2008 |
Low-level quinolone-resistance in multi-drug resistant typhoid.
Topics: Anti-Infective Agents; Antimalarials; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Humans; M | 2008 |
Quinolone resistant enteric fever--problems and remedies.
Topics: Anti-Infective Agents; Drug Resistance, Microbial; Humans; Nalidixic Acid; Salmonella typhi; Typhoid | 1998 |
Nalidixic acid screening test for the detection of decreased susceptibility to ciprofloxacin in Salmonella typhi.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Test | 2001 |
Incidence of river water of Escherichia coli containing R factors.
Topics: Ampicillin; Anti-Bacterial Agents; Chloramphenicol; England; Escherichia coli; Extrachromosomal Inhe | 1970 |
Treatment of typhoid and paratyphoid fever with nalidixic acid.
Topics: Adolescent; Child; Chloramphenicol; Humans; Nalidixic Acid; Paratyphoid Fever; Typhoid Fever | 1970 |
[Typhoid].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Child; Chloramphenicol; Female; F | 1971 |